Vicore Pharma to Participate in the Jefferies Global Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / November 10, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
STOCKHOLM, SE / ACCESS Newswire / November 10, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the Jefferies Global Healthcare Conference.
Location: London, UK
Format: Fireside chat and 1×1 meetings
Date and time: Thursday, November 19, 2026, 12:00-12:25 PM GMT
Participants:
- Ahmed Mousa, Chief Executive Officer
- Hans Jeppsson, Chief Financial Officer
- Jimmie Hofman, Chief Business Officer
- Bernt van den Blink, Chief Medical Officer
- Rob Slack, Chief Scientific Officer
Webcast: Link
For further information, please contact:
Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
Attachments
Vicore Pharma to Participate in the Jefferies Global Healthcare Conference
SOURCE: Vicore Pharma Holding
View the original press release on ACCESS Newswire
Media gallery
